| 33.14 0.97 (3.02%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.81  |
1-year : | 46.5 |
| Resists | First : | 34.09 |
Second : | 39.81 |
| Pivot price | 27.2 |
|||
| Supports | First : | 26.77 |
Second : | 22.25 |
| MAs | MA(5) : | 30.49 |
MA(20) : | 26.18 |
| MA(100) : | 26.84 |
MA(250) : | 26.42 |
|
| MACD | MACD : | 1.8 |
Signal : | 1 |
| %K %D | K(14,3) : | 88.5 |
D(3) : | 89.3 |
| RSI | RSI(14): 73.8 |
|||
| 52-week | High : | 49.5 | Low : | 16.95 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BEAM ] has closed above the upper band by 2.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 76.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 34.13 - 34.26 | 34.26 - 34.36 |
| Low: | 32.02 - 32.17 | 32.17 - 32.3 |
| Close: | 32.9 - 33.15 | 33.15 - 33.34 |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Thu, 25 Jul 2024
Beam Therapeutics (NASDAQ:BEAM) Shares Up 9.7% - MarketBeat
Thu, 25 Jul 2024
SG Americas Securities LLC Sells 8,720 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Wed, 24 Jul 2024
BEAM Factor-Based Stock Analysis - Benjamin Graham - Nasdaq
Tue, 23 Jul 2024
Beam Therapeutics (NASDAQ:BEAM) Now Covered by Analysts at HC Wainwright - Defense World
Wed, 17 Jul 2024
The Latest Updates From the Gene-Editing Clinical Trials (July 2024) - CRISPR Medicine News
Mon, 15 Jul 2024
Beam Therapeutics Announces Transition of Chief Financial Officer - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 7.316e+007 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 13,830 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6089e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -37.4 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 405.2 % |
| Return on Equity (ttm) | -8.5 % |
| Qtrly Rev. Growth | 3.6091e+008 % |
| Gross Profit (p.s.) | -37.12 |
| Sales Per Share | -8.61 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -139 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 1.4 |
| Price to Book value | 0 |
| Price to Sales | -3.86 |
| Price to Cash Flow | 5.35 |
| Dividend | 0 |
| Forward Dividend | 1.18e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|